Current Pharmaceutical Biotechnology

Editor-in-Chief:

Davide Prosperi
Department of Biotechnology and Bioscience
University of Milan Bicocca
Milano
Italy

Back

Become EABM
Become Reviewer

Editorial [ Proteomic Technologies in Translational MedicineGuest Editor: Frode Selheim ] promotion: free to download

Volume:7   Issue: 3
Pp: 133-133
Frode Selheim
DOI: 10.2174/138920106777549740

Proteomic and Computational Methods in Systems Modeling of Cellular Signaling

Volume:7   Issue: 3
Pp: 135-145
R. Kleppe, E. Kjarland and F. Selheim
DOI: 10.2174/138920106777549722

Proteomic-Based Biomarker Discovery with Emphasis on Cerebrospinal Fluid and Multiple Sclerosis

Volume:7   Issue: 3
Pp: 147-158
F. S. Berven, K. Flikka, M. Berle, C. Vedeler and R. J. Ulvik
DOI: 10.2174/138920106777549713

Proteomic Strategies for Individualizing Therapy of Acute MyeloidLeukemia (AML)

Volume:7   Issue: 3
Pp: 159-170
Gry Sjoholt, Siv Lise Bedringaas, Anne P. Doskeland and Bjorn Tore Gjertse
DOI: 10.2174/138920106777549759

Diagnostics, Prognostic and Therapeutic Exploitation of Telomeres and Telomerase in Leukemias

Volume:7   Issue: 3
Pp: 171-183
Laure Deville, Josette Hillion, Michel Lanotte, Philippe Rousselot and Evelyne Segal-Bendirdjian
DOI: 10.2174/138920106777549768

Proteomics Approaches to Elucidate Oncogenic Tyrosine Kinase Signalingin Myeloid Malignancies

Volume:7   Issue: 3
Pp: 185-198
Eystein Oveland, Kari E. Fladmark, Line Wergeland, Bjorn Tore Gjertsen and Randi Hovland
DOI: 10.2174/138920106777549696

Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia

Volume:7   Issue: 3
Pp: 199-207
Nina Anensen, Ingvild Haaland, Clive D'Santos, Werner Van Belle and Bjorn Tore Gjertsen
DOI: 10.2174/138920106777549731

Does Isoform Diversity Explain Functional Differences in the 14-3-3Protein Family?

Volume:7   Issue: 3
Pp: 217-223
E. Kjarland, T. J. Keen and R. Kleppe
DOI: 10.2174/138920106777549777